ImmunityBio, Inc., a vertically-integrated commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include cytokine fusion proteins, vaccine vectors, and cell therapies. The company's platforms have generated nine first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. The company is based in San Diego, California.

ImmunityBio Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mediwound (MDWD) and ImmunityBio (IBRX) with bullish...

Analysts Offer Insights on Healthcare Companies: Mediwound (MDWD) and ImmunityBio (IBRX)

ImmunityBio ( ($IBRX) ) just unveiled an update. On April 6, 2026, ImmunityBio, Inc. announced it had submitted a comprehensive response to a March...

ImmunityBio Addresses FDA Warning on ANKTIVA Promotion

Insiders have been trading these 5 stocks: (($IBRX)), (($KEYS)), (($RBRK)), (($AFL)) and (($MCO)). Here is a breakdown of their recent trades and t...

ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up

Executive Accountability: Patrick Soon-Shiong Named in Securities Action NEW YORK, March 31, 2026 — Levi & Korsinsky, LLP notifies investors that D...

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky

ImmunityBio (IBRX) is facing a securities lawsuit after investors alleged that public statements about Anktiva overstated its capabilities, includi...

ImmunityBio Faces Securities Lawsuit Over Alleged Misleading Statements About Cancer Drug Anktiva

ImmunityBio ($IBRX) shares dropped over 26% on Tuesday after the U.S. Food and Drug Administration (FDA) issued a warning letter to the biotechnolo...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IBRX	$7.48	0.00%	21.51M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IBRX	$7.48	0%	21.51M
3
4
5
6

IBRX

IBRX

No Data Available

Get ImmunityBio Inc. Data in Excel

Get ImmunityBio Inc. Data in Excel